Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1983 May;71(5):1450–1456. doi: 10.1172/JCI110898

Mechanisms of activation of the classical pathway of complement by Hageman factor fragment.

B Ghebrehiwet, B P Randazzo, J T Dunn, M Silverberg, A P Kaplan
PMCID: PMC437009  PMID: 6304147

Abstract

The mechanism by which a fragment of activated Hageman factor (HFf) activates the classical pathway of complement in serum or platelet-poor plasma has been further delineated. When serum or platelet-poor plasma was incubated with various concentrations of HFf, the total complement hemolytic activity was reduced in a dose-dependent manner. This activation appears to be due to the direct interaction of HFf with macromolecular C1, since incubation of purified C1 with HFf resulted in dissociation of the subunits with concomitant reduction of C1r antigenicity that is indicative of C1 activation. HFf-dependent activation was prevented by prior treatment of HFf with the active site-directed inhibitor, H-D-proline-phenylalanine-arginine chloromethyl ketone or with a specific inhibitor of activated HF derived from corn. Incubation of HFf with highly purified C1r also resulted in activation of C1r as assessed directly using a synthetic substrate or indirectly by activation of C1s and consumption of C2. However, incubation of HFf with highly purified C1s resulted in formation of activated C1s (C1s-) but this was less efficient than HFf activation of C1r. We therefore conclude that activation of C1 in macromolecular C1 is the result of HFf conversion of C1r to C1r; activation of C1s then occurs primarily by C-1r and to a lesser degree by the direct action of HFf.

Full text

PDF
1450

Images in this article

1453Image
on p.1453
1453Image
on p.1453
1453Image
on p.1453

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AUSTEN K. F., SHEFFER A. L. DETECTION OF HEREDITARY ANGIONEUROTIC EDEMA BY DEMONSTRATION OF A REDUCTION IN THE SECOND COMPONENT OF HUMAN COMPLEMENT. N Engl J Med. 1965 Apr 1;272:649–656. doi: 10.1056/NEJM196504012721301. [DOI] [PubMed] [Google Scholar]
  2. BORSOS T., RAPP H. J. CHROMATOGRAPHIC SEPARATION OF THE FIRST COMPONENT OF COMPLEMENT AND ITS ASSAY ON A MOLECULAR BASIS. J Immunol. 1963 Dec;91:851–858. [PubMed] [Google Scholar]
  3. Bokisch V. A., Müller-Eberhard H. J., Cochrane C. G. Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med. 1969 May 1;129(5):1109–1130. doi: 10.1084/jem.129.5.1109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Calcott M. A., Müller-Eberhard H. J. C1q protein of human complement. Biochemistry. 1972 Aug 29;11(18):3443–3450. doi: 10.1021/bi00768a018. [DOI] [PubMed] [Google Scholar]
  5. Cochrane C. G., Müller-Eberhard H. J. The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement. J Exp Med. 1968 Feb 1;127(2):371–386. doi: 10.1084/jem.127.2.371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Colman R. W. Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun. 1969 Apr 29;35(2):273–279. doi: 10.1016/0006-291x(69)90278-2. [DOI] [PubMed] [Google Scholar]
  7. Cooper N. R., Müller-Eberhard H. J. A comparison of methods for the molecular quantitation of the fourth component of human complement. Immunochemistry. 1968 Mar;5(2):155–169. doi: 10.1016/0019-2791(68)90100-6. [DOI] [PubMed] [Google Scholar]
  8. Deutsch D. G., Mertz E. T. Plasminogen: purification from human plasma by affinity chromatography. Science. 1970 Dec 4;170(3962):1095–1096. doi: 10.1126/science.170.3962.1095. [DOI] [PubMed] [Google Scholar]
  9. Forbes C. D., Pensky J., Ratnoff O. D. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator. J Lab Clin Med. 1970 Nov;76(5):809–815. [PubMed] [Google Scholar]
  10. Ghebrehiwet B., Silverberg M., Kaplan A. P. Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med. 1981 Mar 1;153(3):665–676. doi: 10.1084/jem.153.3.665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gigli I., Kaplan A. P., Austen K. F. Modulation of function of the activated first component of complement by a fragment derived from serum. I. Effect on early components of complement. J Exp Med. 1971 Dec 1;134(6):1466–1484. doi: 10.1084/jem.134.6.1466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gigli I., Porter R. R., Sim R. B. The unactivated form of the first component of human complement, C1. Biochem J. 1976 Sep 1;157(3):541–548. doi: 10.1042/bj1570541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ginsberg M. H., Jaques B., Cochrane C. G., Griffin J. H. Urate crystal--dependent cleavage of Hageman factor in human plasma and synovial fluid. J Lab Clin Med. 1980 Apr;95(4):497–506. [PubMed] [Google Scholar]
  14. Gorski J. P., Hugli T. E., Müller-Eberhard H. J. C4a: the third anaphylatoxin of the human complement system. Proc Natl Acad Sci U S A. 1979 Oct;76(10):5299–5302. doi: 10.1073/pnas.76.10.5299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Green G. D., Shaw E. Thiobenzyl benzyloxycarbonyl-L-lysinate, substrate for a sensitive colorimetric assay for trypsin-like enzymes. Anal Biochem. 1979 Mar;93(2):223–226. doi: 10.1016/s0003-2697(79)80141-4. [DOI] [PubMed] [Google Scholar]
  16. Harpel P. C., Mosesson M. W. Degradation of human fibrinogen by plasms alpha2-macroglobulin-enzyme complexes. J Clin Invest. 1973 Sep;52(9):2175–2184. doi: 10.1172/JCI107402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Heck L. W., Kaplan A. P. Substrates of Hageman factor. I. Isolation and characterization of human factor XI (PTA) and inhibition of the activated enzyme by alpha 1-antitrypsin. J Exp Med. 1974 Dec 1;140(6):1615–1630. doi: 10.1084/jem.140.6.1615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hojima Y., Pierce J. V., Pisano J. J. Hageman factor fragment inhibitor in corn seeds: purification and characterization. Thromb Res. 1980 Oct 15;20(2):149–162. doi: 10.1016/0049-3848(80)90381-3. [DOI] [PubMed] [Google Scholar]
  19. Kaplan A. P., Austen K. F. A pre-albumin activator of prekallikrein. J Immunol. 1970 Oct;105(4):802–811. [PubMed] [Google Scholar]
  20. Kaplan A. P., Austen K. F. A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med. 1971 Apr 1;133(4):696–712. doi: 10.1084/jem.133.4.696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kaplan A. P. Initiation of the intrinsic coagulation and fibrinolytic pathways of man: the role of surfaces, hageman factor, prekallikrein, high molecular weight kininogen, and factor XI. Prog Hemost Thromb. 1978;4:127–175. [PubMed] [Google Scholar]
  22. Kolb W. P., Kolb L. M., Podack E. R. C1q: isolation from human serum in high yield by affinity chromatography and development of a highly sensitive hemolytic assay. J Immunol. 1979 May;122(5):2103–2111. [PubMed] [Google Scholar]
  23. LEPOW I. H., NAFF G. B., TODD E. W., PENSKY J., HINZ C. F. Chromatographic resolution of the first component of human complement into three activities. J Exp Med. 1963 Jun 1;117:983–1008. doi: 10.1084/jem.117.6.983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  25. MUELLER-EBERHARD H. J., BIRO C. E. ISOLATION AND DESCRIPTION OF THE FOURTH COMPONENT OF HUMAN COMPLEMENT. J Exp Med. 1963 Sep 1;118:447–466. doi: 10.1084/jem.118.3.447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  27. Mandle R. J., Jr, Kaplan A. P. Hageman-factor-dependent fibrinolysis: generation of fibrinolytic activity by the interaction of human activated factor XI and plasminogen. Blood. 1979 Oct;54(4):850–862. [PubMed] [Google Scholar]
  28. Mandle R., Jr, Kaplan A. P. Hageman factor substrates. Human plasma prekallikrein: mechanism of activation by Hageman factor and participation in hageman factor-dependent fibrinolysis. J Biol Chem. 1977 Sep 10;252(17):6097–6104. [PubMed] [Google Scholar]
  29. Mason J. W., Kleeberg U., Dolan P., Colman R. W. Plasma kallikrein and Hageman factor in Gram-negative bacteremia. Ann Intern Med. 1970 Oct;73(4):545–551. doi: 10.7326/0003-4819-73-4-545. [DOI] [PubMed] [Google Scholar]
  30. Polley M. J., Müller-Eberhard H. J. The second component of human complement: its isolation, fragmentation by C'1 esterase, and incorporation into C'3 convertase. J Exp Med. 1968 Sep 1;128(3):533–551. doi: 10.1084/jem.128.3.533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Porter R. R., Reid K. B. Activation of the complement system by antibody-antigen complexes: the classical pathway. Adv Protein Chem. 1979;33:1–71. doi: 10.1016/s0065-3233(08)60458-1. [DOI] [PubMed] [Google Scholar]
  32. Ratnoff O. D., Naff G. B. The conversion of C'IS to C'1 esterase by plasmin and trypsin. J Exp Med. 1967 Feb 1;125(2):337–358. doi: 10.1084/jem.125.2.337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Revak S. D., Cochrane C. G. The relationship of structure and function in human Hageman factor. The association of enzymatic and binding activities with separate regions of the molecule. J Clin Invest. 1976 Apr;57(4):852–860. doi: 10.1172/JCI108361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Saito H. The participation of plasma thromboplastin antecedent (Factor XI) in contact-activated fibrinolysis. Proc Soc Exp Biol Med. 1980 Jun;164(2):153–157. doi: 10.3181/00379727-164-40839. [DOI] [PubMed] [Google Scholar]
  35. Schreiber A. D., Kaplan A. P., Austen K. F. Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest. 1973 Jun;52(6):1402–1409. doi: 10.1172/JCI107313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Silverberg M., Dunn J. T., Garen L., Kaplan A. P. Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate. J Biol Chem. 1980 Aug 10;255(15):7281–7286. [PubMed] [Google Scholar]
  37. Silverberg M., Kaplan A. P. Enzymatic activities of activated and zymogen forms of human Hageman factor (factor XII). Blood. 1982 Jul;60(1):64–70. [PubMed] [Google Scholar]
  38. Tack B. D., Prahl J. W. Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry. 1976 Oct 5;15(20):4513–4521. doi: 10.1021/bi00665a028. [DOI] [PubMed] [Google Scholar]
  39. Valet G., Cooper N. R. Isolation and characterization of the proenzyme form of the C1r subunit of the first complement component. J Immunol. 1974 May;112(5):1667–1673. [PubMed] [Google Scholar]
  40. Valet G., Cooper N. R. Isolation and characterization of the proenzyme form of the C1s subunit of the first complement component. J Immunol. 1974 Jan;112(1):339–350. [PubMed] [Google Scholar]
  41. Weber K., Osborn M. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem. 1969 Aug 25;244(16):4406–4412. [PubMed] [Google Scholar]
  42. Ziccardi R. J., Cooper N. R. Demonstration and quantitation of activation of the first component of complement in human serum. J Exp Med. 1978 Feb 1;147(2):385–395. doi: 10.1084/jem.147.2.385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Ziccardi R. J., Cooper N. R. Development of an immunochemical test to assess C1 inactivator function in human serum and its use for the diagnosis of hereditary angioedema. Clin Immunol Immunopathol. 1980 Mar;15(3):465–471. doi: 10.1016/0090-1229(80)90058-6. [DOI] [PubMed] [Google Scholar]
  44. Ziccardi R. J., Cooper N. R. Physicochemical and functional characterization of the C1r subunit of the first complement component. J Immunol. 1976 Feb;116(2):496–503. [PubMed] [Google Scholar]
  45. da Silva W. D., Eisele J. W., Lepow I. H. Complement as a mediator of inflammation. 3. Purification of the activity with anaphylatoxin properties generated by interaction of the first four components of complement and its identification as a cleavage product of C'3. J Exp Med. 1967 Dec 1;126(6):1027–1048. doi: 10.1084/jem.126.6.1027. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES